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pecially the gastroenterologist should assess the vaccination status of the patient and initiate vaccination
as soon as diagnosis is established.
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Abstract
During the course of disease, a majority of inflammatory 
bowel disease (IBD) patients requires long-term immuno-
suppressive therapy with either immunomodulatory agents, 
biologics, or newer immunosuppressive therapies such as 
Vedolizumab, a selective α4β7 inhibitor, Ustekinumab, an IL 
12/23 p40 inhibitor, or the Janus kinase inhibitor Tofacitinib. 
Due to this, they are at increased risk for infectious diseases, 
many of which are possible to prevent by vaccination. This 
review focuses on recommended vaccinations in IBD pa-
tients and stresses special issues which have to be paid at-
tention to. The aim of the review is to increase gastroenter-
ologists’ awareness of the importance of vaccination and to 
stress why especially the gastroenterologist should assess 
the vaccination status of the patient and initiate vaccination 
as soon as diagnosis is established. 
© 2020 S. Karger AG, Basel
Introduction
The term inflammatory bowel disease (IBD) refers to 2 
main disease subtypes, Crohn’s disease (CD) and ulcer-
ative colitis (UC), which are immune-mediated diseases. 
Due to the immune-mediated nature of these diseases, a 
cornerstone for therapy is immunosuppressive medica-
tions. However, these may carry a higher risk for infec-
tions. A recent review comprising data of 14,590 IBD pa-
tients reported an elevated risk for any infection (OR 1.19, 
95% CI 1.10–1.29) and for opportunistic infections in par-
ticular (OR 1.90, 95% CI 1.21–3.01). In this review, no el-
evated risk for serious infections was reported among pa-
tients treated with biologics (OR 0.89; 95% CI 0.71–1.12) 
[1]. However, a large prospective study, investigating seri-
ous infections in 6,273 patients with CD during a > 5-year 
follow-up period, found an increased risk for serious in-
fections among patients with infliximab (hazard ratio 
[HR] 1.43, 95% CI 1.11–1.84), as well as for patients with 
moderate to severe disease activity (HR 2.24, 95% CI 1.57–
3.19), narcotic analgesic treatment (HR 1.98, 95% CI 1.44–





2.10) [2]. A very recent nationwide population-based 
study by Kirchgesner et al. [3] investigated the risk of seri-
ous and opportunistic infections among IBD patients 
treated with monotherapy with thiopurine or anti-TNF or 
a combination therapy of both during 6 years. Among 
190,694 IBD patients 8,561 serious infections and 674 op-
portunistic infections were observed. The risk for serious 
infections was the highest being on combination therapy 
when compared with anti-TNF monotherapy (HR 1.23, 
95% CI 1.05–1.45). Besides it was elevated among patients 
on anti-TNF monotherapy when compared to thiopurine 
monotherapy (HR 1.71, 95% CI 1.56–1.88). Patients on 
anti-TNF monotherapy were at high risk for mycobacte-
rial infection (HR 1.98, 95% CI 1.15–3.40) and bacterial 
infection (HR 2.38, 95% CI 1.23–4.58) but at lower risk for 
opportunistic viral infections (HR 0.57, 95% CI 0.38–0.87) 
when compared to thiopurine monotherapy [3]. 
Particularly the risk of vaccine-preventable diseases 
such as influenza, pneumococcal disease, or hepatitis B is 
increased among patients with IBD, and low rates of vac-
cination are reported [4]. A very recent retrospective co-
hort study investigated risk differences with regard to in-
fluenza infection between 140,480 IBD and non-IBD pa-
tients. Overall, IBD patients had a higher risk for 
influenza infection (incidence rate ratio [IRR] 1.54, 95% 
CI 1.49–1.63), and treatment with corticosteroids was 
identified as the only medication class independently as-
sociated with an increased influenza risk [5]. A study of 
Melmed et al. [4] among 169 patients with IBD reported 
that only 9 and 28% of patients were vaccinated against 
pneumococcal disease and influenza, respectively. Only 
28% were vaccinated against hepatitis B [4]. Main reasons 
for nonimmunization included lacking awareness and 
concerns about potential side effects. These factors were 
also reported among patients and their treating physi-
cians in a study by Yeung et al. [6]. The study detected 
that only 14.3% of questioned gastroenterologists took a 
vaccination history from their patients. Besides, 18.6% of 
gastroenterologists were not aware of the importance of 
an up-to-date vaccination status prior to starting an im-
munosuppressive therapy [6]. A study by Wasan et al. [7] 
found that 52% of gastroenterologists took a vaccination 
history from their IBD patients. However, one additional 
problem with regard to low vaccination rates seems to be 
a disagreement on responsibility for who is doing it. 
While the study by Wasan et al. [7] reported that 83% of 
gastroenterologists thought that vaccinations should be 
administered by the primary care physician (PCP), a 
study among PCPs found that 20% of them did not feel 
responsible for vaccine administration [8]. 
For 2 main reasons, the gastroenterologist should take 
the vaccination history and complete immunizations if 
necessary: (i) the indication for an immunosuppressive 
therapy is usually confirmed and started by a gastroen-
terologist and thus he or she can update the vaccination 
status even prior to starting therapy; (ii) IBD patients at-
tend the gastroenterologist more frequently than a PCP, 
and therefore, the gastroenterologist has more chances of 
checking and completing the vaccination status. The gas-
troenterologist would also be the one asked for traveling 
recommendations with regard to vaccination. A recent 
study evaluated the proportion of patients with immune-
mediated inflammatory diseases (IMID) seeking advice 
at a University Hospital Travel Clinic on the one hand 
and demographics, travel destinations, and vaccination 
patterns on the other hand. The study found that almost 
2% of travelers seeking advice were patients with an 
IMID and 34% were on immunomodulatory or -sup-
pressive medication. They did not differ with regard to 
reasons for travel or destination and therefore similar 
vaccinations were required compared to non-IMID trav-
elers [9].
As a consequence of the mentioned reasons, knowl-
edge on generally recommended vaccinations as well as 
travel recommendations, familiarity with specifically rel-
evant immunizations in IBD patients, and the awareness 
on contraindicated vaccinations in immunosuppressed 
individuals are crucial for the practicing gastroenterolo-
gist. This review therefore summarizes the literature and 
vaccination recommendations for IBD patients. 
Vaccination Recommendations
Key messages regarding vaccination in IBD patients:
1. Vaccinations neither do not cause gastroenterologi-
cal or other (auto-) immune diseases nor do they induce 
exacerbation of the disease.
2. In IBD patients without immunosuppressive thera-
py, there are no specific contraindications for vaccination 
with inactivated or live vaccines. 
3. As in a majority of patients an immunosuppressive 
therapy will be started, the vaccination status of the pa-
tient should be determined at time of diagnosis, and rec-
ommended vaccinations should be administered. Inde-
pendent of history and vaccination status, serologies re-
garding measles and varicella should be performed to 
check for antibody protection. The same approach ap-
plies to yellow fever serology in a person under immuno-
suppressive therapy who intends to travel to a yellow fe-
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ver endemic area and who received the yellow fever vac-
cination in the past.
4. Due to higher efficacy, vaccinations should be ad-
ministered during remission of disease.
5. Vaccinations should preferentially be administered 
before the start of an immunosuppressive therapy – ide-
ally at least 4 weeks before starting the immunosuppres-
sive therapy. 
6. If an immunosuppressive therapy has already been 
started, vaccinations should be administered when im-
munosuppressive therapy is at the lowest possible dose. 
7. If an immunosuppressive therapy has already been 
started, it is generally safe to use inactivated vaccines in 
these patients; however, the immunogenicity may be re-
duced. 
8. If an immunosuppressive therapy has already been 
started live vaccinations should be avoided as there is a 
risk of replication of the attenuated microorganisms and 
invasive infections. However, live vaccines may be used 
with caution in selected immunosuppressed patients. De-
pending on the drug used, different intervals for adminis-
tration of a live vaccine after immunosuppressive therapy 
are advised.
9. The immune response to a booster vaccine given 
during immunosuppressive therapy is less affected than 
the immune response to a primary vaccine dose. 
10. Due to the induction of higher affinity antibody 
responses, longer lasting immune responses and memory 
responses conjugate vaccines should be used rather than 
polysaccharide vaccines. 
11. General recommendations for basic vaccinations 
also apply to IBD patients.
12. There are several specific vaccination recommen-
dations for IBD patients as they may require a more com-
prehensive protection. These include:
a. The annual seasonal inactivated influenza vaccina-
tion
b. Pneumococcal vaccinations 
c. Vaccination against hepatitis B is recommended in 
all seronegative IBD patients
d. Vaccination against human papillomavirus (HPV) 
is recommended in young IBD patients 
e. Herpes zoster (HZ) vaccination is recommended in 
patients aged 50 years and above. If available, the inacti-
vated vaccine (Shingrix®) should be used. Among pa-
tients on immunosuppressive therapy only the inactivat-
ed vaccine is recommended.
13. In immunosuppressed patients, a serology should 
be performed after completion of a primary vaccination 
course if the respective serology is available. 
14. In addition to checking the patient’s vaccination 
status, the vaccination status of household members and 
other close contacts should be checked and they should 
also be vaccinated if indicated (especially against measles, 
mumps, rubella [MMR], varicella, and influenza). 
15. If the immunocompromised IBD patient is not 
protected against measles and/or varicella, administra-
tion of immunoglobulins or antivirals has to be consid-
ered in case of exposure.
16. As a precaution, oral typhoid vaccination (Vivot-
if®) should be avoided in IBD patients under immuno-
suppressive therapy, although no published data on this 
topic exist. 
When vaccinating immunosuppressed individuals, 
one has to differentiate between live vaccines and inacti-
vated vaccines. Pertaining to live vaccines (MMR, vari-
cella, HZ, yellow fever), there are different points of inter-
est. Not only the class of immunosuppressive medication 
but also the dosage can play a role for decision making. 
Moreover, if an immunosuppressive therapy is paused or 
terminated, depending on the medication, different time 
intervals before administering a live vaccine are recom-
mended. A detailed listing can be found in Table 1.
Inactivated vaccines can be addressed differently. As 
there are no safety concerns, they can be used in IBD pa-
tients with and without immunosuppressive therapy 
without restrictions. There are no limitations for any 
medication group or dose of immunosuppressive thera-
py. They may, however, be less immunogenic and there 
are some vaccine-specific recommendations. A summary 
of recommendations of different societies for inactivated 
as well as for live vaccines is shown in Table 2. 
Inactivated Vaccinations
Influenza
The risk for influenza infection and influenza-associ-
ated hospitalization is elevated among patients with IBD 
[5]. A study focusing on the risk for hospitalization due 
to vaccine preventable pneumonias among IBD patients 
revealed an increased risk for hospitalization due to in-
fluenza-associated pneumonia among UC patients with 
a low income (OR 1.86; 95% CI 1.46–2.37) [10]. Safety, 
efficacy, as well as adverse events of influenza vaccina-
tion among IBD patients have been evaluated in several 
studies [11–15]. Overall, response to vaccination was ap-
propriate. However, there have been several studies re-
porting a reduced immune response among patients on 
immunosuppression [14, 16–20]. Still, due to an in-
creased risk of infection, even a suboptimal protection by 





seasonal influenza vaccination is recommended in all 
guidelines and should be carried out annually [22–28]. 
The inactivated quadrivalent vaccine, which has been 
shown to be well tolerated, should be used. In addition to 
the patient himself/herself close contacts should be vac-
cinated. Contacts should receive the inactivated vaccine 
[28]. 
Pneumococcal Disease
IBD patients are at increased risk for pneumonia (IRR 
1.82; 95% CI 1.75–1.88) [29]. Several medications as bio-
logic medications, steroids, thiopurines, proton-pump 
inhibitors, and narcotics were shown to be associated 
with pneumonia [29]. Besides, among patients with 
pneumonia, there is an elevated risk for pneumonia-as-
sociated mortality (OR 3.6, 95% CI 2.9–4.5) [30]. A large 
recent Danish cohort study including almost 75,000 IBD 
patients revealed an increased risk of invasive pneumo-
coccal disease [31]. The risk was especially increased be-
fore and after diagnosis of IBD, suggesting that the risk 
increase might be due to general alterations in the im-
mune response of IBD patients. This is also underlined 
by the fact that IBD medication, even biologics, had a 
limited effect on the elevated risk [31]. Pneumococcal 
vaccination is recommended for IBD patients in all cur-
rent guidelines [22–28]. The most common scheme rec-
ommended is pneumococcal conjugate vaccine once, 
followed by pneumococcal polysaccharide vaccine 23 
(PPSV23) 8 weeks to 6 months after and a final booster 
dose of PPSV23 5–6 years later. However, some coun-
tries, such as Switzerland, recommend only the pneumo-
coccal conjugate vaccine to avoid a phenomenon called 
“hyporesponsiveness,” which may be induced by a 
PPSV23. 




–  Systemic: only short term (<2 weeks) or low dose (<20 mg/day of prednisone or 
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– Maintenance physiologic doses (replacement therapy)
– Non-systemic glucocorticoids (topical or injections)
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–  Systemic and high dose (≥20 mg per day of prednisone or equivalent [adult] or  






































Table 2. Vaccination recommendations in IBD patients (reprinted from [22] with permission from Elsevier)
Professional society, country, year





MMR Recommended at least 6 weeks before 
starting IT
Recommended at least 3
weeks before starting IT
Not recommended 
Contraindicated during IT
Recommended at least 2 weeks before 
starting IT
Varicella zoster Recommended at least 1–3
months before starting IT
Contraindicated during IT
Recommended at least 3









Yellow fever Not recommended
Contraindicated during IT
Inactivated vaccines
Tdap-polio Administer vaccine if not given
over the past 10 years or give
Tdap if Td ≥2 years, with a
booster dose every 10 years





Not recommended but possible during IT A single dose is recommended in 
patients with IT
Hepatitis B Recommended (3 doses at 1, 1–2 and 4–6 
months; if no response 1 month after 
finishing last dose then  revaccinate with 
double dose) 
Possible during IT
Recommended (double dose at 0,  
1 and 2 months; if no response 1 month 
after finishing last dose  
then revaccinate with double dose)
Possible during IT
Not recommended but possible during IT
Meningococcal
vaccination
Not recommended but possible during IT A single dose of Men ACWY is 
 recommended in patients with IT
Pneumococcal
vaccination
Recommended (PCV13 and PPSV23 8 weeks later; re-vaccinate with a single dose of PPSV23 5 years after)
Possible during IT
Recommended (PCV13 and PPSV23 
8 weeks later; second dose of PPSV23 
5–10 years after, third dose at 65 
years)
Possible during IT
Recommended (PCV13 and 
PPSV23 8 weeks later;  revaccinate 
with a single dose of PPSV23 5 
years after)
Possible during IT
Recommended (a single dose of 
PPSV23 with a second dose 5 years in 
case of IT)
Possible during IT






18 years in patients with IT
(3 doses 0, 2 and 6 months
with HPV4)
Possible during IT
Not recommended but possible during IT
Influenza Recommended (annual vaccine with the TIV) 
Possible during IT
Hepatitis A Recommended (2 doses at 0
and 6–12 months or 0 and 12–18
months with a booster dose
>10 years)
Possible during IT
Not recommended but possible during IT
IBD, inflammatory bowel disease; ACIP, Advisory Committee on Immunisation Practices; ECCO, European Crohn’s and Colitis Organization; PHAC, Public Health Agency of Canada; ATAGI, Australian Technical Advisory Group on Immunisation; HCSP, 
Haut Conseil de la Santé Publique; STIKO, Vaccination Committee of the State of Saxony; BCG, bacillus calmette-guérin; IT, immunosuppressive therapy; MMR, measles, mumps, rubella; Tdap, Tetanus-diphteria-acellular pertussis; PCV13, 13-quadrivalent pneu-






There are several studies evaluating antibody response 
to vaccination against tetanus, diphtheria, or pertussis. 
The latest study evaluated the persistence of tetanus, 
diphtheria, and pertussis-specific antibodies among 90 
IBD patients on therapy either with thiopurines, anti-
TNF monotherapy, or combination of both. Compared 
to healthy controls, IBD patients showed significantly re-
duced antibody concentrations against pertussis and 
diphtheria, being the lowest among patients on anti-TNF 
therapies [32]. A prospective controlled study from 2015 
investigated serological immune responses to tetanus and 
pertussis booster vaccination in 84 IBD patients. This 
study found a reduced response rate among immunosup-
pressed patients, the lowest among those on a combined 
biologic and immunomodulator therapy [33]. Tetanus, 
diphtheria, and pertussis vaccination should be given ac-
cording to general country-specific vaccination guide-
lines. Booster doses are generally recommended every 10 
years. 
Hepatitis B
Patients with IBD are at increased risk for infections 
with hepatitis B for several reasons. On the one hand, 
there is an elevated risk due to surgical interventions and 
blood transfusions [34, 35]. Besides it is known that 
among patients under immunosuppressive therapy, a 
hepatitis B virus (HBV) reactivation can be induced and, 
in the worst case, result in acute liver failure [36–41]. This 
is why hepatitis B should be screened for prior to initia-
tion of anti-TNF therapy. Nevertheless, a recent retro-
spective study in 3,357 IBD patients revealed that the 
overall screening rate for hepatitis B was low [42]. How-
ever, it increased from 8.1% in 2003 to 43.2% in 2011 [42]. 
Vaccination against hepatitis B for IBD patients is recom-
mended in several guidelines. A recent systematic review 
and meta-analysis evaluated the response rate to HBV 
vaccination [41]. Thirteen studies with 1,688 patients 
were included. The pooled vaccination serological re-
sponse rate, defined as anti-HBs antibody titers of > 10 
mlU/mL, was 61%. Factors predictive for a better im-
mune response were young age and vaccination during 
remission (RR 1.62; 95% CI 1.15–2.29). Moreover, pa-
tients without immunosuppressive therapy had a higher 
chance of response compared with patients on immuno-
modulatory (RR 1.33; 95% CI 1.08–1.63) or anti-TNF 
therapy (RR 1.57; 95%-CI 1.19–2.08) [41]. Recently, 2 
publications reporting on HBV seroprotection among 
children with IBD were published. deBruyn et al. [43] re-
ported on vaccine coverage and seroprotection among 
156 children with IBD. Brenner et al. [44] reported on 
seroprotection and revaccination among 159 children 
with IBD. While 71% (82/115) of patients reported on by 
deBruyn et al. [43] had HBV seroprotection, the seropro-
tection rate among patients reported on by Brenner et al. 
[44] was only 26% (41/159). One major reason for these 
differences, Brenner et al. [44] point out might be due to 
regional variations in vaccine timing, as well as the fact 
that among the patients included by deBruyn et al. [43], 
there were no patients on biologics while patients includ-
ed by Brenner et al. [44] were all on biologics and there-
fore possibly more immunocompromised. Interestingly, 
among the patients included by Brenner et al. [44] giving 
one booster dose increased seroprotection to 79% (26/33) 
while a complete booster vaccination resulted in seropro-
tection among 98% (58/59) of patients. 
Due to the low response rates, Marin et al. [45] evalu-
ated different vaccination protocols. One included study 
by Gisbert et al. [46] reported an increase of protection 
from 41 to 75% when using a faster double-dose schedule 
compared to a single-dose protocol. The faster double-
dose protocol consists of double dose of Engerix-B® at 0, 
1, and 2 months. This schedule is therefore recommend-
ed by the ECCO guideline focusing on vaccination among 
IBD patients [24]. Moreover, antibody levels should be 
checked 1–3 months after completion of the vaccination 
schedule to ensure response [47]. 
Hepatitis A
While the American College of Gastroenterology 
(ACG) guideline recommends vaccination against hepa-
titis A among all IBD patients, the ECCO guideline only 
recommends it to patients before travel to endemic areas 
[24, 28]. Patients should receive 2 vaccinations at the time 
points 0 and 6 months. In 2014 a study by Park et al. [48] 
was published, focusing on the immunogenicity of hepa-
titis A vaccination. Among the 419 included IBD patients 
97.6% showed a seroconversion after 2 hepatitis A vac-
cine doses; however, it was lower among patients on anti-
TNF medication (92.4%). Furthermore, it was also lower 
among patients on therapy with ≥2 immunosuppres-
sants.
Human Papillomavirus
It is known that a compromised immune system can 
increase the risk for dys- or neoplastic alterations of the 
cervix [49]. Besides it is known that smoking as well as 
an HPV infection is associated with cervical cancer [28, 
50, 51]. It is still subject of discussion whether IBD itself 
is accompanied by an increased risk for cervical cancer 
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[49]. However, many studies have addressed the possible 
impact of immunosuppressive therapy on the develop-
ment of cervical abnormalities among IBD patients. An 
extensive review by Hazenberg et al. [49] summarizes the 
literature published to date. The authors conclude that 
IBD itself, especially CD, might be associated with an in-
creased risk of cervical abnormalities, but not of cervical 
cancer. The cumulative dose of thiopurines appears to be 
correlated with cervical high-grade dysplasia (HGD), es-
pecially among patients with CD. Patients treated with a 
combination therapy do not seem to have a higher risk 
for cervical HGD or cervical cancer; however, the au-
thors emphasize that data have to be interpreted with 
caution as in the majority of the included studies infor-
mation with regard to duration and dose of the immuno-
suppressive medication are missing. In 2015, Allegretti el 
al. [52] conducted a meta-analysis to assess the risk of 
HGD and cervical cancer among female IBD patients. 
Data of 77,116 IBD patients from 5 cohort studies, and 3 
case–control studies were included. The meta-analysis 
revealed an elevated risk for cervical HGD or cancer 
among immunosuppressed IBD patients compared to 
healthy controls (OR 1.34; 95% CI 1.23–1.46). Although 
data are not homogeneous, it is beyond doubt that a cor-
relation between immunosuppression among IBD pa-
tients, HPV infection, and cervical abnormalities exist. 
Therefore, regular gynecologic screening for cervical 
cancer is recommended for female IBD patients [24]. 
The American College of Obstetricians and Gynecolo-
gists even recommend annual screening for women with 
a history of chronic immunosuppressive therapy [53]. 
Although immunosuppressed women are at an increased 
risk for cervical anomalies rates of cervical testing are 
suboptimal. A study by Long et al. [54] revealed that only 
70.4% of female IBD patients received cervical testing at 
least once every 3 years. In a recent study by Waszczuk 
et al. [55], among 150 female IBD patients, only 69% re-
ported of regular cervical testing (30% annually, 32% ev-
ery 2–3 years, 7% every 5 years). Moreover, only 10% of 
female IBD patients were aware of the existing HPV vac-
cination recommendation. In addition to regular gyne-
cological checkups, HPV vaccination is the major mean 
for reducing the incidence of cervical dysplasia [49, 56]. 
Beside of increased risk for HPV-associated cervical neo-
plasic alterations, there is an increased risk of HPV-relat-
ed anal carcinoma among CD patients with perianal dis-
ease involvement [57]. HPV vaccination is recommend-
ed to young patients (through 26 years) in most guidelines 
[22]. It is of note that not only female but also male pa-
tients should be vaccinated. Vaccination with a quadri-
valent HPV vaccine (HPV-6, -11, -16, and -18) as well as 
by a bivalent vaccine (HPV-16 and -18) results in vacci-
nation rates of 95–100% [45, 58]. Recently, a 9-valent 
HPV vaccine (HPV-6, -11, -16, -18, -31, -33, -45, -52, and 
-58) has been introduced. In a prospective study includ-
ing 37 female IBD patients on immunosuppressive ther-
apy, antibody response to vaccination with the quadriva-
lent HPV vaccine Gardasil was evaluated. Seropositivity 
after 3 doses was 100% for types 6, 11, and 16 and 96% 




IBD patients are at increased risk of developing HZ, 
as has been shown in several large studies [59–62]. In 
2013, Long et al. [59] compared the HZ risk among 
108,000 IBD patients compared with 434,000 non-IBD 
individuals. The HZ risk was increased among IBD pa-
tients (IRR 1.68; 95% CI 1.60–1.76). The study also 
showed that anti-TNF medication (OR 1.81; 95% CI 
1.48–2.21), corticosteroids (OR 1.73; 95% CI 1.51–1.99), 
thiopurines (OR 1.85; 95% CI 1.61–2.13), but especially 
a combination therapy with anti-TNF medication and 
thiopurines (OR 3.29; 95% CI 2.33–4.65) were indepen-
dently linked to HZ infection [59]. A very recent study 
by Nugent et al. [63] assessed HZ infections among IBD 
and non-IBD individuals before and after introduction 
of HZ vaccination in 2009 in Manitoba. The authors 
found a higher risk of HZ infections among IBD patients 
compared to non-IBD individuals (incidence rate [IR] 
9.2/100,000 vs. 7.2/100,000, p < 0.0001). The incidence 
of HZ infections increased during the study period de-
spite an introduction of HZ vaccination [63]. Khan et al. 
[60] investigated the HZ risk among 13,000 IBD patients 
on therapy with 5-aminosalicylic acid compared to 
35,500 non-IBD individuals. The authors found an in-
creased HZ infection rate among IBD patients (HR 1.72; 
95% CI 1.51–1.96). In a second study, the authors com-
pared the HZ risk among the 5-aminosalicylic acid only 
therapy group to IBD patients with other medications. 
Again, the risk was highest among patients on a combi-
nation therapy with thiopurines and anti-TNF medica-
tion (HR 1.65; 95% CI 1.22–2.23), followed by thiopu-
rines alone (HR 1.47; 95% CI 1.31–1.65). However, there 
was no risk increase among patients on anti-TNF medi-
cation alone (HR 1.15; 95% CI 0.96–1.38) [60]. Another 
group high at risk for HZ infections is patients treated 
with the Janus kinase inhibitor Tofacitinib. Winthrop et 





facitinib phase II/III/ongoing, open-label, as well as 
long-term extension UC trials. HZ IR was 4.07 (3.14–
5.19) in the overall cohort over a mean range of 509.1 
days (1–1,606). The IR was highest among old patients 
aged ≥65 years (IR 9.55 [4.77–17.08]), Asians (IR 6.49 
[3.55–10.89]), and patients with prior anti-TNF failure 
(IR 5.38 [3.86–7.29]). Although some data suggest that 
among IBD patients HZ infection is not only an infec-
tion of the older patient [61, 65, 66], most guidelines 
recommend the HZ vaccination only in patients aged 50 
or 60 years and above. The ACG for example recom-
mends an immunization against HZ among IBD pa-
tients over the age of 50 [28]. However, until the end of 
2017, the only available vaccine was a live vaccine (Zos-
tavax®, Merck). As mentioned before, usually live vac-
cines are not recommended in immunosuppressed indi-
viduals. However, the ACG guideline as well as the Cen-
ters for Disease Control and Prevention and the 
Advisory Committee on Immunization Practices rec-
ommended it in certain subgroups of immunosup-
pressed patients (low-dose therapy with methotrexate 
[< 0.4 mg/kg/week], azathioprine [< 3.0 mg/kg/day], or 
mercaptopurine [< 1.5 mg/kg/day]) [28, 67]. These rec-
ommendations are in line with the recommendations by 
the Infectious Disease Society of America [47]. Besides, 
a recent study by Khan et al. [68] suggests that even 
among patients on anti-TNF medication vaccination 
with the live vaccine may be safe. However, only around 
21% of patients eligible for vaccination were vaccinated, 
as a recent study by Khan et al. [69] showed. 
With regard to the high risk for HZ among patients 
treated with Tofacitinib Pfizer in their Tofacitinib-con-
taining Xeljanz® label (summary of product characteris-
tics) recommends not to use live vaccines among patients 
under treatment with Tofacitinib [70]. 
However, since 2018 a new inactivated vaccine is avail-
able (Shingrix®, GlaxoSmithKline). The vaccine is ad-
ministered at 2 time points, 0 and 2–6 months. The vac-
cine has shown to significantly reduce the risk of HZ by 
> 90% [71]. Limited data in immunosuppressed patients 
(stem cell transplant recipients and HIV patients) suggest 
that Shingrix® was immunogenic and safe in these pa-
tient groups [72, 73]. As it is an inactivated and immuno-
genic vaccine, it is now recommended by the Advisory 
Committee on Immunization Practices [74]. 
Live Vaccines
Yellow Fever
There are no data on yellow fever vaccination in pa-
tients with IBD under immunosuppressive therapy ex-
cept of one case report which reported of a patient treated 
with infliximab accidentally live vaccinated against yel-
low fever. No yellow fever viremia was detected and the 
patient developed antibodies [75]. 
Wilckens et al. [76] focused on the immunization sta-
tus of patients with IBD. The authors found that beside of 
low vaccination rates against other infections among 102 
IBD patients, of those patients who had traveled only 1% 
had been vaccinated for yellow fever [76]. 
Vaccination with the yellow fever live vaccine is con-
traindicated among patients under immunosuppressive 
therapy. An inactivated form of the vaccine does not exist. 
If a patient plans to travel to a yellow fever endemic region 
and has been vaccinated against yellow fever before an 
antibody measurement should be performed irrespective 
of time point of vaccination.
Varicella
Varicella virus is highly contagious and IBD patients, 
especially when treated with immunosuppressive thera-
py, are at increased risk of infection and complications 
[77, 78]. The ACG guideline recommends assessment for 
prior exposure and vaccination if naïve [28]. However, as 
the vaccine is a live vaccine, the vaccination has to be ad-
ministered at least 1 month before initiation of immuno-
suppressive therapy according to ACH guidelines. This is 
in line with the ECCO guideline. In contrast to the ACG 
guideline, the ECCO recommends a minimum interval of 
3 weeks between vaccination and start of immunosup-
pression [24]. Two vaccine doses, at least 1 month apart, 
should be administered.
Measles, Mumps, Rubella
There is only scarce data on measles, mumps, and ru-
bella vaccination among IBD patients. Lately a study con-
ducted by Caldera et al. [79] evaluated measles, mumps, 
and rubella antibody concentrations among IBD patients 
on immunosuppressive medication. The authors found 
no difference with regard to antibody concentrations 
among IBD patients compared to non-IBD patients. Re-
sults did not differ for various types of immunosuppres-
sive medications. 
Similarly to other live vaccines, the MMR vaccination 
should be administered before the start of an immuno-
suppressive therapy. Two vaccine doses, at least 1 month 
apart, should be given. According to the ACG guidelines 
MMR vaccination should be administered at least 6 weeks 
before starting immunosuppression; according to the 
ECCO guidelines 3 weeks are sufficient [24, 28]. 
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Household Immunizations
Beside focusing on vaccination of the IBD patient, 
treating physicians should think of vaccinating close con-
tacts as well. Especially the ACG guideline focuses on this 
fact [28]. It is, for example, known that around 90% of 
susceptible close contacts will get varicella after exposure 
to a person with disease [28]. 
Household members of immunosuppressed IBD pa-
tients should be vaccinated against influenza, HZ, mumps, 
measles, rubella, and varicella. Waszczuk et al. [80] speak 
of a “cocoon strategy” of vaccination, meaning that vac-
cinating close contacts will protect vulnerable patients 
from infectious diseases. If available inactivated vaccines 
should be preferred, however, live vaccines can safely be 
administered (MMR, varicella, zoster) [28]. Transmis-
sions from an immunocompetent vaccinated person to 
an immunosuppressed person have not been demon-
strated for MMR or HZ vaccine. Rare cases of varicella 
transmission after vaccination have been reported from 
vaccinees with skin lesions [47]. Thus, if skin lesions de-
velop after varicella or live HZ vaccination, the vaccinated 
persons should avoid close contact with the immunosup-
pressed patient.
Conclusion
Patients with IBD are at increased risk of infections. 
This risk is increased even higher during immunosup-
pressive therapy. Therefore, the vaccination status should 
be assessed as soon as the disease is diagnosed and miss-
ing vaccinations should be administered, ideally before 
immunosuppressive therapy is started. However, not 
only the patient him-/herself but also treating physicians 
often lack knowledge on this subject area. As a majority 
of IBD patients is of young age and might therefore not 
otherwise consult a PCP and as IBD patients at the begin-
ning of their disease will be at closest contact with the 
gastroenterologist, the gastroenterologist should be the 
doctor assessing and completing the vaccination status in 
IBD patients. IBD patients should not only complete the 
vaccination status for standard vaccination as those 
against dTaP, varicella or MMR but they should also re-
ceive vaccinations specifically recommended for IBD pa-
tients, such as influenza, pneumococcal, HPV, or HZ vac-
cination. 
In addition to vaccinating the IBD patient, household 
members as well as close contacts should be vaccinated 
especially against highly contagious infectious diseases to 
avoid disease transmission to IBD patients. 
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